Partitioning Heritability of Regulatory and Cell-Type-Specific Variants across 11 Common Diseases  by Gusev, Alexander et al.
ARTICLE
Partitioning Heritability of Regulatory and
Cell-Type-Specific Variants across 11 Common Diseases
Alexander Gusev,1,* S. Hong Lee,2 Gosia Trynka,3,4,5,6,16 Hilary Finucane,7 Bjarni J. Vilhja´lmsson,1
Han Xu,8 Chongzhi Zang,8 Stephan Ripke,9,10 Brendan Bulik-Sullivan,9,10 Eli Stahl,11
Schizophrenia Working Group of the Psychiatric Genomics Consortium, SWE-SCZ Consortium,
Anna K. Ka¨hler,12 Christina M. Hultman,12 Shaun M. Purcell,9,10,11 Steven A. McCarroll,10
Mark Daly,6,9,10 Bogdan Pasaniuc,13 Patrick F. Sullivan,12,14 Benjamin M. Neale,6,9,10 Naomi R. Wray,2
Soumya Raychaudhuri,3,4,5,6,15 and Alkes L. Price1,6,*
Regulatory and coding variants are known to be enriched with associations identified by genome-wide association studies (GWASs) of
complex disease, but their contributions to trait heritability are currently unknown. We applied variance-component methods to
imputed genotype data for 11 common diseases to partition the heritability explained by genotyped SNPs (h2g ) across functional cate-
gories (while accounting for shared variance due to linkage disequilibrium). Extensive simulations showed that in contrast to current
estimates from GWAS summary statistics, the variance-component approach partitions heritability accurately under a wide range of
complex-disease architectures. Across the 11 diseases DNaseI hypersensitivity sites (DHSs) from 217 cell types spanned 16% of imputed
SNPs (and 24% of genotyped SNPs) but explained an average of 79% (SE ¼ 8%) of h2g from imputed SNPs (5.13 enrichment; p ¼ 3.7 3
1017) and 38% (SE¼ 4%) of h2g from genotyped SNPs (1.63 enrichment, p¼ 1.03 104). Further enrichment was observed at enhancer
DHSs and cell-type-specific DHSs. In contrast, coding variants, which span 1% of the genome, explained<10% of h2g despite having the
highest enrichment. We replicated these findings but found no significant contribution from rare coding variants in independent
schizophrenia cohorts genotyped on GWAS and exome chips. Our results highlight the value of analyzing components of heritability
to unravel the functional architecture of common disease.Introduction
Recent work by ENCODE and other projects1,2 has shown
that specific classes of variants can have complex and
diverse impacts on cell function and phenotype.3–10
Although the importance of coding variation has long
been understood, these projects identified other genomic
regions that can contribute to function and highlighted
the role of regulatory variants. With many potentially
informative functional categories and competing biolog-
ical hypotheses, quantifying the contribution of variants
in these categories to heritability of complex traits would
inform trait biology and focus genetic mapping.
The availability of significantly associated variants from
hundreds of genome-wide association studies (GWASs)11
has opened one avenue for quantifying enrichment.
Indeed, 11% of GWAS hits lie in coding regions,11 57%
of noncoding GWAS hits lie in broadly defined DNaseI hy-
persensitivity sites (DHSs; spanning 42% of the genome),3
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The Americandistribution of GWAS association statistics exhibits en-
riched p values in coding regions and UTRs.12 Analysis of
DHS subclasses and other histone marks has revealed a
complex pattern of cell-type-specific relationships with
known disease associations.6 Recent work has also shown
that functional enrichment can be leveraged for increasing
association mapping power.13
Although relative enrichment has been documented,
the question of how much each category contributes
to disease heritability remains unanswered.14,15 Recently,
investigators have used variance-component methods to
estimate the total additive variance explained by all
genotyped SNPs (h2g ),
16,17 and to estimate the h2g of many
quantitative and dichotomous traits.18–22 We propose
joint estimation of h2g from functional-category-specific
variance components for assessing enrichment. In contrast
to analyses of top GWAS hits, the variance-component
approach leverages the entire polygenic architecture of
each trait and accounts for pervasive linkage disequi-
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simulations showed that this approach provides accurate
genome-wide estimates of functional enrichment in
diverse genetic architectures. We applied variance-compo-
nent methods to functional categories in GWAS- and
exome-chip data from over 100,000 samples in 11 traits.Material and Methods
Estimating Enrichment of h2g with Variance
Components
For a single component of genotyped (or imputed) SNPs, we
define h2g , an underlying parameter in the population, as the r
2
between the true phenotype and the best linear prediction over
those SNPs. With multiple components, the goal of the parti-
tioned analysis is to quantify the h2g directly explained by SNPs
in each functional category while excluding tagging of SNPs in
other categories. We thus define the h2g for each functional cate-
gory as the r2 between the true phenotype and the prediction
only from SNPs in that functional category when all functional
categories are jointly analyzed for a best linear prediction.
When SNPs are in LD, this definition remains valid as long as
the individual causal effect sizes are independent, as we would
expect in highly polygenic traits. For disease traits, we model
the phenotype (and corresponding h2g ) by using the liability-
threshold model, in which individuals whose underlying unob-
served continuous liability exceeds a threshold are labeled as
disease case subjects.19,23
We estimate h2g jointly across multiple variance components,
each constructed from variants belonging to nonoverlapping
functional categories. The underlying model assumes that SNP
effect sizes are drawn from a normal distribution with category-
specific variance. (We note that the normality assumption is unre-
alistic; previous work in the single-variance-component case has
indicated that this does not introduce bias, although modeling a
more realistic mixture distribution can increase precision.24
Because of computational constraints, we do not consider mixture
distributions here.) The model relates the observed phenotypic
covariance to a weighted sum of genetic relationship matrices
computed from SNPs in each category. The joint estimate allows
all components to compete for shared variance due to LD.
Formally, for a functional categories each containing the set of










whereWs is the genotype at SNP s, b
i
s is the effect size at SNP s in
category i and is drawn from category-specific normal distribution
bi  Nð0; s2i Þ, and e is the residual effect e  Nð0; s2e Þ. We assume
that for each annotation i, SNPs normalized to have mean 0 and
variance 1 are contained in the matrix Wi. The variance of the







where each Ki represents a genetic-relationship matrix (GRM)
computed directly from the SNPs in annotation i as
Ki ¼WiW 0i

Mi:536 The American Journal of Human Genetics 95, 535–552, NovembThe corresponding s are then jointly inferred with the REML algo-








The inverse of the final average-information matrix yields an es-
timate of the corresponding error-covariance matrix of the vari-
ance-component estimates.25 We use the error-covariance matrix
and delta method26 to compute SEs on h2g and the percentage of
h2g while accounting for error correlations (referred to here as
the analytical SE27). All estimates of h2g were transformed to the li-
ability scale19 with the prevalence values in Table S1 (available
online). We evaluated the accuracy of the analytical SE for both
quantitative and ascertained traits and found it to correspond
well to the true SD under reasonable polygenicity (see Appendix
A). Meta-analysis estimates were computed with inverse-variance
weighting:28 given individual study estimates h2gi, analytical SEi,















Enrichment is computed for each category i as the ratio of the
percentage of h2gi (the percentage of h
2
g in category i) to the percent-
age of SNPi (the percentage of SNPs in category i) and is tested for
significance by Z score relative to a null of 1:0 with the (likewise-
rescaled) analytical SE. Under the assumption that all causal vari-
ants are typed, this statistic is equivalent to the relative risk that a
SNP in category i is causal in comparison to an average SNP. To
achieve unbiasedness, the estimate of h2g is not constrained to lie
inside the plausible 0–1 bound, which can lead to negative esti-
mates in rare instances.Estimating Enrichment from Summary Statistics
We considered alternative methods for estimating functional
enrichment from summary association statistics. The simplest
approach is to directly count the number of individual genome-
wide-significant variants in each functional annotation and
compare to the null expectation from all SNPs (or random SNPs
matched on certain features). This approach can either include
all significant markers or restrict to the most significant variant
in each locus. The genome-wide-significant-SNP approach has
been extended to the full distribution of association statistics for
quantifying overall p value enrichment.3 Over increasingly restric-
tive p value thresholds, the fraction of SNPs passing a given
threshold and belonging to each category is computed and
normalized by the category-specific genome-wide fraction. The
distributions are then inspected visually for enrichment or
assessed by permutation. For completeness, we considered two
additional methods—stratified quantile-quantile (Q-Q) plots12
and Bayesian hierarchical modeling (fgwas)13—which assess func-
tional enrichment but are primarily focused on improving associ-
ation mapping power (see Discussion).Data Sets Analyzed
11 Diseases from WTCCC1 and WTCCC2
We analyzed seven traits from Wellcome Trust Case Control Con-
sortium 1 (WTCCC1) and four traits from WTCCC2 for a totaler 6, 2014
47,000 samples (Table S1). Estimates of h2g are particularly sensitive
to individually small artifacts or batch effcts,19,29 and we followed
the rigorous quality-control (QC) protocol outlined previously21
by removing any SNPs that were below a minor allele frequency
(MAF) of 0.01, were above 0.002 missingness, or deviated from
Hardy-Weinberg equilibrium at a p value below 0.01. For each
case-control cohort, we removed SNPs that had differential miss-
ingness with a p value below 0.05. We excluded one of any pair
of samples with kinship entries R 0.0519 and performed five
rounds of outlier removal whereby all individuals more than
6 SDs away from the mean along any of the top 20 eigenvec-
tors were removed and all eigenvectors were recomputed30
(Figure S1). For all autoimmune diseases analyzed (rheumatoid
arthritis [RA], Crohn disease [CD], type 1 diabetes [T1D], ulcerative
colitis [UC], multiple sclerosis [MS], and ankylosing spondylitis
[AS]), we also excluded from the analysis any SNPs in the well-
studied major histocompatibility complex (MHC) locus (chr6:
26–34 Mb), which is known to have a complex LD structure,
and many heterogeneous variants of strong effect for these traits.
TheWTCCC1 samples were phased and imputed as described in
Gusev et al.21 TheWTCCC2 samples were split into two cohorts by
platform, and each cohort was imputed separately according to
the following protocol. All samples in a cohort were phased
together in 10 Mb blocks with HAPI-UR (Haplotype Inference for
Unrelated Samples)31 (see Web Resources) and three rounds of
phasing and consensus voting. All phased samples in a cohort
were then imputed in 1 Mb blocks with IMPUTE232 (see Web Re-
sources) and the 1000 Genomes33 Phase I integrated haplotypes
(September 2013 release; see Web Resources) with no singletons.
Where relevant, the Oxford recombination map34 was used.
Markers with an information (info) score greater than 0.5 were
retained. Finally, SNPs were excluded if they met any of the
following criteria in any case or control population: Hardy-Wein-
berg p value < 0.05, per-locus missingness > 0.05, MAF < 0.01, or
case-control differential missingness p value < 0.05.
Schizophrenia Cohort from the Psychiatric Genomics Consortium
We analyzed 24,926 schizophrenia (SP) subjects and 33,271 con-
trol individuals from 33 cohorts from the Psychiatric Genomics
Consortium (PGC2); they were typed on a variety of platforms,
quality controlled, and imputed to the 1000 Genomes reference
panel as previously described35 (Tables S1 and S2). Because of
computational constraints, we split the cohort into four subgroups
of individuals typed on similar platforms; each contained roughly
10,000–20,000 samples. We performed all analyses on the inter-
section of well-imputed SNPs within each subgroup, ranging
from four to fivemillion, and reportedmeta-analyzed results. Indi-
vidual study identifiers and 20 multidimensional-scaling compo-
nents were included as fixed-effect covariates in all analyses.
Swedish SP Exome Chip
We analyzed 12,674 Swedish samples typed on GWAS and exome
chips (Tables S1 and S3). The exome chip yielded 238,652 SNPs
(including monomorphic sites), of which 10,567 were also typed
on a mix of Affymetrix GWAS chips (exome-chip calls were re-
tained). The GWAS-chip data contained an intersection of
163,051 SNPs typed on all platforms in addition to per-platform
imputation from 1000 Genomes for a total of 5,053,934 SNPs
imputed on all platforms. Principal-component analysis (PCA) of
the GWAS data revealed a large cluster of ‘‘homogenous’’ Swedish
samples and clines related to Northern Swedish and Finnish
admixture (Figure S2). After excluding samples that (1) were not
typed on both GWAS and exome chips, (2) failed QC, (3) were
PCA outliers by 6 SDs, or (4) were in a pair with GRM values >The American0.05 (close relatives), we retained a total of 8,967 samples, of
which 6,375 were of ‘‘homogenous’’ Swedish ancestry. In all of
our analyses, rare variants had a MAF < 0.01, and common
variants had a MAF R 0.01. Simulations were performed on the
homogenous samples (without principal components). We per-
formed analyses of real phenotypes on the homogeneous samples
and included the top 20 principal components as covariates (to ac-
count for any residual population structure; analyses on the full
cohort are reported in Tables S23 and S25).Functional Annotations
We annotated the genome by using six primary categories (Table
S4): (1) coding, (2) UTR, (3) promoter, (4) DHS in any of 217 cell
types, (5) intronic, and (6) intergenic. Each SNP was then assigned
a unique annotation defined by the first of these categories with
which it was annotated, resulting in six nonoverlapping variance
components (the DHS category was thus restricted to distal re-
gions). Each resulting category exhibited similar average allele fre-
quency and imputation accuracy, although the DHS category had
systematically lower LD36 (Table S5). We also computed the ‘‘effec-
tive’’ number of SNPs in each category by using an LD-based
metric that does not depend on sample size.36,37 Table S6 shows
that this metric was not substantially different from the actual per-
centage of SNPs used in imputed data, given that DHSs harbored
slightly more effective SNPs (15.7% SNPs versus 18.9% effective
SNPs) as a result of lower LD. For the imputed categories analyzed
here, the differences in the percentage of SNPs, percentage of effec-
tive SNPs, and percentage of physical size were relatively minor. A
greater difference was observed for genotyped SNPs: 23.6% of DHS
SNPs corresponded to 33.6% of effective SNPs, suggesting that
DHS enrichments from genotyped data might be indicative of
better tagging.
For the DHS annotation, we used DNase sequencing libraries
downloaded from ENCODE and Epigenome Roadmap projects
in May 2012 and merged biological replicates into a single library
(GEO accession numbers are available in Table S7). We used
BOWTIE v.1.038 to align raw read sequences to UCSC Genome
Browser hg19 and used MACS v.2.0 with false-discovery rate <
0.01 (the default cutoff) and Benjamini–Hochberg correction39
to call DHS peaks. For the primary analysis, all peaks were merged
into a single DHS annotation spanning 16% of the genome. We
note that 98% of the primary DHS annotation was covered by
the DHSs released by Maurano et al.3 (spanning 37% of the
genome), and 67% of the primary DHS annotation was covered
by the DHSs analyzed in Thurman et al.4 (spanning 15% of the
genome). For the cell-type-specific analysis, duplicate lines were
merged to form a final set of 83 unique cell types. The resulting
annotations are available for download (see Web Resources).
Segway-chromHMM combined genome segmentations40 were
downloaded for six cell lines (see Web Resources). All regions clas-
sified as enhancers or weak enhancers were then combined into a
single enhancer annotation. DNaseI digital genomic footprinting
(DGF) regions were downloaded for 57 cell lines (see Web Re-
sources). All regions from the narrow-peak classification were
then merged into a single DGF annotation.Simulation Framework
The goal of our simulations was to demonstrate that the parti-
tioned h2g properly recovers the heritability explained by causal
variants in a given functional category under a variety of disease
architectures. We performed simulations in genotyped andJournal of Human Genetics 95, 535–552, November 6, 2014 537
Figure 1. Estimates of Functional Enrichment under the Null
We simulated a polygenic disease architecture in imputed data
with no functional enrichment (see text). Simulated phenotypes
were tested with the variance-component method (top) from
3,000 simulations and with p value enrichment (bottom) from
538 The American Journal of Human Genetics 95, 535–552, Novembimputed data in 4,414 samples from theWTCCC1 coronary artery
disease (CAD) case-control cohort together with the six main
functional annotations to evaluate robustness and accuracy of
the proposed variance-component method and the p-value-
enrichment approach; we note that the genome-wide-signifi-
cant-SNP approach is subsumed by the latter and is not reported
separately in most analyses. For each simulation, 10% of the (gen-
otyped or imputed) SNPs were randomly sampled to be causal, and
normally distributed effect sizes were assigned to each SNP such
that each explained equal variance in expectation. Additive phe-
notypes were then constructed, and random noise was added for
an overall h2g of 0.50. Except when evaluating h
2
g between geno-
typed and imputed SNPs, we did not hide causal variants from
the analyses, corresponding to the assumption that all causal var-
iants are typed. We evaluated the variance-component model by
using multiple components with GCTA in the unconstrained
mode. For approaches based on summary statistics, we computed
Z scores, SEs, and p values for the univariate regression of each SNP
to a simulated phenotype.Results
Simulations
We first evaluated the calibration of the methods in simu-
lations of no enrichment by assuming a MAF-independent
architecture where causal variants were uniformly sampled
from the genome (seeMaterial andMethods). We observed
no significant deviations from the null for any categories
estimated by variance components or p value enrichment
(Figure 1). To evaluate possible biases due to MAF-depen-
dent architectures,21,41,42 we also considered a low-fre-
quency architecture where only SNPs with a MAF below
0.05 can be causal and a DHS-low-frequency architecture
where causal DHS variants are drawn from MAF below
0.05 and all other variants are drawn from any MAF (Fig-
ures S3 and S4). Results were generally similar to the
MAF-independent architecture, although variance-compo-
nent estimates exhibited slight but statistically significant
deviations for the promoter and UTR categories, which
were very small and in tight LD with each other.
We next considered simulations with maximal enrich-
ment, where all causal variants were drawn from a single
functional category. MAF-independent results for the cod-
ing and DHS categories are shown in Figure 2 (see Figure S5
for other results). The variance-component estimate of the
percentage of h2g was again around 100% for the true causal
category and 0% for all others. The plots of p value enrich-
ment correctly demonstrated significant enrichment for
five of the categories, but not the DHS category, which,
when causal, was not significantly different from the
null. This lack of enrichment at DHSs and not at other
large categories was most likely due to the uniquely lower100 simulations. In the variance-component subplot, the thin
line represents the median, boxes represent the first and third
quartiles, and whiskers represent the 1.53 interquartile range
from the first to the third quartile. A subplot of p value enrichment
shows 1.963 SE as shaded regions.
er 6, 2014
Figure 2. Estimates of Functional Enrichment from a Single Causal Category
We simulated a polygenic disease architecture in imputed data with causal SNPs drawn from a single functional category, corresponding
to complete enrichment. Simulated phenotypes were tested with the variance-component method (top) from 200 simulations and with
p value enrichment (bottom) from 100 simulations. In the variance-component subplot, the thin line represents the median, boxes
represent the first and third quartiles, and whiskers represent the 1.53 interquartile range from the first to the third quartile. Subplots
of p value enrichment show 1.963 SE across simulations as shaded regions. For each method, only the coding-causal and DHS-causal
scenarios are shown (additional simulations appear in Figures S6 and S7).LD of DHS SNPs (Table S5). For the small categories (cod-
ing, UTR, and promoter), true causals in one category
always yielded false p value enrichment in the others
because of their close proximity and high LD (Figure 2; Fig-
ures S6 and S7). In the MAF-dependent scenarios, the vari-
ance-component estimate of h2g was nearly unbiased: it had
slight but significant inflation at the coding and UTR cate-
gories when they contained 100% of h2g (Figure S8). Plots of
p value enrichment exhibited similar patterns as in the
MAF-independent simulations, and the DHS category
was further falsely depleted (Figure S7).
To investigate the differences between genotype- and
imputation-based estimates, we partitioned h2g of cate-
gory-specific phenotypes simulated from imputed SNPsThe Americanby using components constructed from genotyped SNPs
only. If the genotypes are reasonable proxies for imputed
variants, 100% of h2g should again be partitioned into
each truly causal category. Instead, we observed significant
deviations for all of the categories, and h2g was partitioned
into nearby categories as a result of incomplete tagging
(Figures S9 and S10). In particular, less than half of the h2g
at imputed DHSs was partitioned into the DHS category
in genotype data. Thus, estimates produced with only gen-
otyped SNPs can severely underestimate enrichment. The
difference between genotyped and imputed simulations
suggests that estimates from imputed SNPs could also un-
derestimate the true enrichments or depletions for rare
causal variants that are absent from 1000 Genomes or areJournal of Human Genetics 95, 535–552, November 6, 2014 539
poorly imputed. We investigated this possibility by using
the exome-chip SP data (see below). We separately assessed
the impact of imputation error by simulating phenotypes
with induced genotype noise proportional to the per-SNP
imputation quality score (info score; Supplementary infor-
mation S3 in Marchini et al.43) but observed no significant
biases in null or causal simulations (Tables S8 and S9), most
likely as a result of the stringent postimputation QC.
We evaluated multiple other complex architectures with
respect to LD (see Appendix A) but observed significant
bias in only one deliberately severe scenario: causal vari-
ants sampled from intronic and intergenic regions either
directly adjacent to or proximal to a DHS (within 1 kb of
a DHS boundary). Although no substantial false DHS
heritability was observed in genotyped SNPs, the imputed
DHS component picked up 50% (0–500 bp) and 20% (500–
1,000 bp) of the non-DHS h2g (Figure S11). Given our
findings that genotyped SNPs are expected to greatly un-
derestimate DHS enrichment, we consider genotyped and
imputed estimates to be lower and upper bounds, respec-
tively, on the true causal enrichment.
Heritability of Functional Categories across
11 Diseases
We analyzed a total of 11 WTCCC1 and WTCCC2 pheno-
types.44–46 After QC,21 the seven WTCCC1 traits each
included an average of 1,700 affected subjects and a set
of 2,700 shared control subjects; the four WTCCC2 traits
included 1,800–9,300 affected subjects and 5,300 shared
control subjects (see Material and Methods; Table S1). In
all analyses of autoimmune traits, SNPs in the well-studied
MHC region were excluded, although inclusion of the
MHC as a separate component did not significantly affect
the results. Each cohort was imputed to the 1000 Genomes
reference panel, yielding four to six million SNPs per trait
after QC (see Material and Methods; Table S1). This anal-
ysis is expected to be skewed toward the autoimmune
traits, which composed 6/11 traits analyzed and 20,461/
30,158 affected subjects analyzed. We computed meta-
analysis values by using inverse-variance weighting with
the analytical SE to account for different levels of error
across h2g estimates. After meta-analysis, resulting SEs
were adjusted for the use of shared controls by genomic
control (unless otherwise stated), and p values were
computed by a simple Z score comparing the mean enrich-
ment and adjusted SE to a null of 1.0 enrichment. Esti-
mating enrichment from shifted functional annotations
yielded null enrichments and p values (Tables S10 and
S11), confirming that this null is comparable to random
SNP comparisons used in previous work.3,11,40,47
Combined results meta-analyzed across all traits are re-
ported in Figure 3 (Tables S10, S12, and S13). In genotyped
data, DHS variants (spanning 24% of genotyped SNPs)
were the most significantly enriched and explained an
average of 38% (SE ¼ 4%) of the total h2g , a 1.63 enrich-
ment (p ¼ 1.0 3 104). Coding variants were the only
other category significantly enriched (after six tests were540 The American Journal of Human Genetics 95, 535–552, Novembaccounted for) and explained 4% (SE ¼ 1%; p ¼ 1.1 3
103). All enrichments or depletions were stronger when
imputed SNPs were analyzed in terms of both significance
and information content, consistent with our previous
simulations (Figures S9 and S10; Table S16). Variants in
DHSs again exhibited the greatest h2g and most significant
enrichment: imputed DHS SNPs explained an average of
79% (SE ¼ 8%) of the total h2g , a 5.13 enrichment (p ¼
3.7 3 1017). The enrichment varied across traits
(Figure S12; Table S14), and there was a nominally signifi-
cant difference between the six autoimmune traits (AS,
CD, MS, RA, T1D, and UC) and the five nonautoimmune
traits (SP, bipolar disorder, CAD, hypertension, and type
2 diabetes [T2D]) at 5.53 and 3.33, respectively (p ¼
0.01 for difference without accounting for shared control
subjects). Coding variants exhibited the greatest overall
enrichment at 13.83 (p ¼ 1.8 3 103) but accounted for
8% of h2g because of the much smaller category size. Corre-
spondingly, we observed a significant depletion for both
intronic regions (0.13; p ¼ 4.9 3 109) and intergenic re-
gions (0.13; p < 1020) and h2g that was not significantly
different from 0. We note that compared to genotyped
SNPs, imputation in these traits generally does not explain
additional h2g ,
21 but it can more precisely partition heri-
tability into functional categories. We performed addi-
tional simulations mimicking the enrichment observed
in imputed data with 8,300 causal variants (as inferred in
a large GWAS of a polygenic trait48) and found that 79%
of heritability was explained by imputed DHS SNPs, 8%
was explained by imputed coding SNPs, and the remainder
was uniformly drawn from the other variant categories.
This ‘‘realistic’’ scenario yielded much weaker estimates of
enrichment from genotyped SNPs, and they were similar
to estimates from genotyped SNPs in real data (Figure 3).
We considered alternative estimation procedures to rule
out potential biases. Although we allowed individual
values of h2g to fluctuate outside the 0–1 bound on vari-
ance to achieve unbiased estimates prior to averaging
across traits,49 a constrained analysis yielded similar re-
sults (see Table S15). Individual point estimates escaping
the 0–1 bound were consistent with our imputed simula-
tions under realistic enrichment, which showed that the
percentage of h2g for DHSs exceeded 1.0 10% of the time,
whereas the percentage of h2g for intronic and intergenic
regions fell below 0.0 30% and 23% of the time, respec-
tively, for a typical 7,000-sample cohort. Using flat instead
of inverse-variance weighting yielded a comparable esti-
mate such that DHS SNPs explained an average of 85%
(SE ¼ 15%) of h2g . With the flat weighting, the SD of
imputed DHS estimates across different traits was 48%,
which corresponds to a SD of 32% in the true unobserved
values after the analytical SE of each estimate is accounted
for (Table S14). We further evaluated the robustness of
these estimates and found that biases arising from
analytical SEs, ancestry, or case-control ascertainment
were unlikely to significantly affect the enrichment (see
Appendix A).er 6, 2014
Figure 3. Functional Partitioning of SNP Heritability across 11 Traits
(Top panels) Joint estimates of the percentage of h2g from six functional components are shown in filled bars (meta-analyzed over 11
traits). The null expectation, equal to the percentage of SNPs in each category, is shown by dashed, unfilled bars, and p values report
the difference from this expectation. Fold enrichment relative to the null expectation is shown in parentheses below each category.
The left panel shows results from analyses of genotyped SNPs only, and the right panel shows analysis of genotyped and 1000 Genomes
imputed SNPs. Error bars show 1.963 SE after adjustment for shared controls.
(Bottom panels) Partitioned h2g in simulations of a ‘‘realistic’’ trait where DHS and coding variants explained 79% and 8% of h
2
g , respec-
tively (with no enrichment elsewhere). Filled bars show the mean inferred percentage of h2g from genotyped (left) and imputed (right)
SNPs over 100 simulations. Patterned bars show the simulated true partition. Error bars show 1.963 SE (on average, SEs on imputed data
were 2.23 higher than SEs on genotype data as a result of the abundance of new variants).To investigate whether enrichment in h2g from all SNPs at
known loci was consistent with the genome-wide esti-
mates, we partitioned the h2g explained by SNPs within 1
Mb of published GWAS loci for each trait (NHGRI GWAS
catalog;11 see Web Resources) (Figure S13). Because someThe Americantraits had a small number of loci, the DHS component
was jointly analyzed with only a single other component
containing all non-DHS SNPs. We again observed a highly
significant DHS enrichment in imputed data and a sig-
nificant difference between the genotyped and imputedJournal of Human Genetics 95, 535–552, November 6, 2014 541
Figure 4. Enrichment from GWAS Summary Statistics
(Left panel) Estimates of p value enrichment are averaged over 11
analyzed traits and are restricted to minimum p value thresholds
(x axis) for which at least one association meeting the threshold
was observed in every trait.
542 The American Journal of Human Genetics 95, 535–552, Novembestimates (p ¼ 7.3 3 1014). We observed a marginally sig-
nificant difference between the DHS enrichment at known
loci versus genome-wide in the imputed data (3.63 versus
5.53, p ¼ 0:003). Although it does not pass multiple-test
correction, this p value suggests that genome-wide-signifi-
cant SNPs of large effects might be less enriched with DHS
variants than the rest of the genome.
We have shown by simulation that estimates from gen-
otyped SNPs are expected to provide a lower bound on
enrichment or depletion and that estimates from imputed
SNPs are biased upward only when causal variants are very
close to the annotation boundary. For brevity, subsequent
results focus primarily on the analysis of imputed SNPs.
Comparison to Estimates of Enrichment from
Summary Statistics
We compared our imputed variance-component estimates
of 5.13 DHS enrichment for the 11 traits to the DHS
enrichment of genome-wide-significant variants identified
in these data or from published loci (NHGRI GWAS
catalog;11 see Web Resources). The enrichments from
genome-wide-significant variants were much smaller
(0.913 and 1.743 for variants in these data and published
loci, respectively; Table S17). This is roughly consistent
with previous results indicating that 57% of noncoding
GWAS hits (from any trait) lie in broadly defined DHSs
spanning 42% of the genome (1.43 noncoding enrich-
ment; 1.23 overall enrichment) and that this percentage
increases to 77% of noncoding GWAS hits when SNPs in
perfect LD with a DHS SNP are included (1.83 noncoding
enrichment; 1.63 overall enrichment).3 Similarly, 30% of
the noncoding GWAS hits analyzed in Maurano et al.3
lay in our DHS annotation, yielding a comparable 1.83
noncoding enrichment. Extending to the full distribution
of association statistics did not reveal significant DHS
enrichment in any of these traits (Figure 4, left panel;
Figure S14). This is consistent with our previous simula-
tions showing the variance-component approach to be
more effective than the p-value-enrichment approach at
identifying DHS enrichment from complex-disease archi-
tectures (Figure 2).
We sought to further confirm this observation by ex-
tending our simulations to a single large cohort with real-
istic levels of enrichment on the basis of the above results.
We simulated the ‘‘realistic’’ level of enrichment (see
above) in 33,000 combined WTCCC2 samples, corre-
sponding to a large GWAS. We then conducted a standard
GWAS on the simulated traits and plotted functional
enrichment by using p value enrichment (see Material
and Methods). The strategy yielded enrichment at coding(Middle panel) p value enrichment from a ‘‘realistic’’ simulation.
(Right panel) Variance-component enrichment from a ‘‘realistic’’
simulation. Realistic traits were simulated with DHS and coding
variants explaining 79% and 8% of h2g , respectively, and with
computed GWAS statistics in a cohort of 32,000 samples. Shaded
regions and error bars represent the SE from meta-analysis (left)




Figure 5. Hierarchical Analysis of Functional Enrichment
DHS variants were further partitioned into three subcategories: predicted enhancers (A), cell-type-specific DHSs (B), and DGF targets (C).
Each block contains (on the top line) the functional category and fraction of the genome (in parentheses) and (on the bottom line) the
fraction enriched in relation to the rest of the genome and the p value of enrichment in relation to the parent category (in parentheses).
DHS enrichment of 4.73 nonsignificantly differed from 5.13 in Figure 3 as a result of additional free parameters.variants through the full distribution of association statis-
tics (Figure 4, middle panel). However, proximal categories
such as UTR and promoter, which were truly depleted, also
appeared enriched through tagging of significant coding
variants. DHS variants were the least-enriched noninter-
genic category, even though they made the single largest
contribution to heritability. This was likely due to lower
power to detect DHS SNPs as a result of their lower average
effect size (relative to that of coding SNPs) and less LD. On
the other hand, applying the variance-component strategy
to the simulated cohorts correctly recovered the enrich-
ment factors (Figure 4, right panel). These simulations
further demonstrate that GWAS p values, although
partially informative, can yield false-positive and false-
negative enrichment to make functional interpretation
difficult, motivating further development of methods
that can produce robust estimates of partitioned heritabil-
ity from summary statistics.
Analysis of PGC2 SP Data
We replicated our functional-enrichment results in an in-
dependent cohort of 58,197 samples from PGC2 (Tables
S1 and S2). In the PGC2 data, the imputed DHS
enrichment was significant at 3.23 (SE ¼ 0.29, p ¼ 1.4 3
1013), and the intergenic category was significantly
depleted at 0.33 (SE¼ 0.06, depletion p< 13 1020; Table
S18). For comparison, the WTCCC2 analysis restricted to
SP produced a nonsignificant DHS enrichment of 2.63
(SE ¼ 1.47, p ¼ 0.28) and intergenic h2g of 0.43 (SE ¼
0.27, depletion p ¼ 0.02; Table S14). The consistency ofThe AmericanWTCCC2 and PGC2 estimates indicates that platform arti-
facts are unlikely to be a major confounder. Moreover, the
substantially lower SE in this large cohort demonstrates the
effectiveness of our methods at characterizing a single
complex trait. As in our previous simulations, p value
enrichment did not identify substantial enrichment at
DHS variants (Figure S15).
Partitioning h2g within DHSs
We further partitioned DHS enrichment in the WTCCC1
data into functional subcategories to assess significance
in relation to all DHSs. We used Segway-chromHMM com-
bined classifications of enhancer regions40 to partition
DHSs (15.7% of the genome) into those that overlapped
predicted enhancers (3.2% of the genome) and those
that did not (Figure 5A). The enhancer DHSs explained
31.7% (SE ¼ 3.3%) of the total h2g , yielding an enrichment
of 9.83 versus all SNPs (1.93 versus all DHSs; p ¼ 5.1 3
104). We also partitioned DHSs into regions that were
called in two or fewer cell types (‘‘specific’’; after merging
similar tissues) and those that were not (Figure 5B). We
observed a significant enrichment for cell-type-specific
DHSs (6.13 versus all SNPs; 1.33 versus all DHSs; p ¼
3.2 3 103). The enrichment was not significant when
we repeated this analysis for enhancer and nonenhancer
DHSs separately. We next split the DHSs into SNPs overlap-
ping and not overlapping the ENCODE database of DGF
regions (8.5% of the genome), which are expected to
precisely map sites where regulatory factors bind to the
genome50 (Figure 5C). We observed no difference in h2gJournal of Human Genetics 95, 535–552, November 6, 2014 543
Table 1. Cell-Type- and Phenotype-Specific DHS Enrichment
Tissue Type Cell Type
Autoimmune Nonautoimmune
PublishedGenotyped Imputed Genotyped
Blood Primary T helper 1 cells 5.8 (4.2 3 106) 10.2 (1.3 3 1012) 2.1 (3.5 3 101) Maurano et al.3 (CD)
leukemia cells 3.5 (6.7 3 106) 4.7 (5.3 3 1010) 1.0 (9.8 3 101) –
lymphoblastoid cells 3.3 (1.1 3 105) 4.9 (5.4 3 1011) 1.0 (9.4 3 101) Maurano et al.3 (MS)
CD8þ primary cells 3.0 (3.0 3 104) 5.4 (1.8 3 1010) 1.0 (9.6 3 101) Trynka et al.6 (RA)
Fetal kidney fetal right renal pelvic cells 5.4 (1.4 3 104) 8.2 (5.7 3 108) 1.5 (7.4 3 101) –
Bone marrow CD14þ monocytes 4.1 (1.6 3 104) 5.7 (2.2 3 107) 1.3 (7.6 3 101) Maurano et al.3 (MS)
Fetal thymus Fetal thymus cells 2.6 (4.0 3 104) 4.5 (3.2 3 109) 0.8 (6.6 3 101) –
Fold enrichment of h2g reported for cell-type-specific DHSs observed as significant in genotype data (after adjustment for 83 cell types tested). Wemeasured enrich-
ment in comparison to h2g at DHSs to account for the background DHS enrichment. Results are shown separately frommeta-analyses of six autoimmune traits and
five nonautoimmune traits. Instances where enrichment was also observed in Trynka et al.6 or Maurano et al.3 are indicated.between these DHSs and other DHSs (1.03, p ¼ 0.90).
However, DGF annotations were collected for only a subset
of DHS cell types analyzed, and analysis in additional cell
types is needed. Lastly, we partitioned the h2g by using an
expanded DHS annotation (including regions overlapping
coding regions, UTRs, and promoters) into the remaining
five major categories (Table S19), which yielded 34.43
enrichment at DHS coding variants versus all SNPs (5.33
versus all DHSs, p ¼ 1.35 3 103) and 13.23 enrichment
at DHS promoter variants versus all SNPs (2.33 versus all
DHSs, p ¼ 7.90 3 103). Notably, unlike the non-DHS in-
trons, DHS introns did not show substantial depletion
(0.93 versus all DHSs, p ¼ 0.037).
To investigate the role of specific cell types, we separately
estimated enrichment in h2g for DHSs in each of 83 unique
cell types (see Material and Methods). For each trait and
cell type, we estimated h2g jointly from three components
corresponding to DHSs observed in that cell type, other
DHSs not observed in that cell type, and all other SNPs;
we assessed enrichment in relation to all DHSs. On the
basis of our previous observation of heterogeneity, we
performed meta-analyses across the six autoimmune traits
(excluding the MHC) and across the five nonautoimmune
traits. We observed seven cell types that were significantly
enriched in autoimmune traits in genotype data (we
conservatively adjusted for 83 tests, although the cell types
are highly correlated), and none were significantly en-
riched in nonautoimmune traits (Table 1). Four of these
seven cell types have previously been implicated in auto-
immune diseases: Trynka et al.6 found that GWAS hits
for RA were enriched within H3K36me3 peaks from
CD8þ primary cells (at p ¼ 0.0042), and Maurano et al.3
found that nominally significant SNPs in a GWAS of CD
were enriched within DHS peaks from primary T helper 1
cells and that nominally significant SNPs in a GWAS of
MS were enriched in DHS peaks from lymphoblastoid
and monocyte CD14þ cells. The remaining three signifi-
cant cell types were leukemia cells, fetal pelvis cells, and
fetal thymus cells (additional nominally significant cell544 The American Journal of Human Genetics 95, 535–552, Novembtypes are listed in Table S20). The enrichment was typically
observed in all autoimmune traits individually; CDwas the
least enriched on average (2.83), and UC was the most en-
riched on average (5.13; Table S21). As before, the signal
was stronger and more significant when we included
imputed SNPs (Table 1).
On the basis of the hypothesis that most regulatory sites
lie at the center of the called DHS peaks, we considered the
enrichment after progressively narrowing the DHS annota-
tions. Specifically, we trimmed the ends of each DHS peak
(without removing any individual peaks) to a maximum
length set such that the resulting overall DHS annotation
covered 1%, 5%, or 10% of the physical genome. We
then tested these three narrowed annotations in two
models: (1) a univariate model in which h2g was inferred
from only the narrowed DHS component, thereby
including any tagged heritability from other functional
categories; and (2) a six-component model in which the
full DHS component was replaced with the narrowed
DHS component and the remaining DHS SNPs were
distributed into the intron and other components. We
found the DHS centers to be particularly strongly enriched
(Table S22); the 1% annotation explained 19.8% of the to-
tal h2g in the multivariate model (p ¼ 2.6 3 106) and
61.0% of the total h2g in the univariate model. For compar-
ison, the coding component covering roughly 1% of the
genome explained 30.0% of the total h2g in the univariate
model. The monotonic increase in h2g from narrowed an-
notations is further evidence of enrichment at the DHS
centers. We caution that this experiment might have
been particularly susceptible to bias from causal variants
very close to the annotation boundary.
Unbiased Estimates of h2g with Rare and Common
Variants
We separately analyzed a cohort of 2,500 SP subjects and
3,875 control subjects who were of homogenous Swedish
origin and had been typed on both GWAS and exome
chips (see Material and Methods; Tables S1 and S3) toer 6, 2014
Table 2. h2g of SP from Exome Chip




All 0.370 5 0.040 –
Noncoding 0.317 5 0.042 –
Coding 0.158 5 0.034 –
Jointly
Noncoding 0.291 5 0.028 79%5 8%
Coding 0.079 5 0.034 (p ¼ 1.2 3 102) 21%5 6%
Coding (rare) 0.037 5 0.029 (p ¼ 1.0 3 101) 10%5 7%
Coding (common) 0.042 5 0.017 (p ¼ 7.7 3 103) 11%5 4%
Estimates of h2g (adjusted for biases due to LD; see Figure S17 and Table S23)
are reported from variance components in the homogenous Swedish subpop-
ulation. The top section shows estimates that include tagging of variants in
other classes. The bottom section shows joint estimates accounting for tagged
variance due to LD. The p values from a likelihood-ratio test are shown in
parentheses.investigate the possible contribution of rare coding vari-
ants to missing heritability,51 defined as the gap between
our genome-wide estimates of h2g and the total narrow-
sense heritability. The exome-chip variants were primarily
rare and consisted of 18% singletons and 64% nonsingle-
tons with a MAF below 0.01. A concern is that h2g estimates
from exome-chip data can be substantially biased as a
result of the abundance of rare variants.21,41,42 To address
this, we performed simulations across the full causal-allele
frequency spectrum and found that joint estimates from
two frequency-stratified42 components computed from
rare (MAF% 0.01) and common (MAF > 0.01) SNPs elim-
inated most of the observed bias. Subsequently adjusting
each component for LD completely eliminated bias for
normalized effect sizes (Figure S17) and yielded the most
accurate estimate for standard effect sizes (Figure S18).
We report estimates from joint components with (Table 2)
and without (Table S23) LD adjustment.
We partitioned the heritability explained by GWAS-chip
and exome-chip data into three separate variance compo-
nents: noncoding, rare coding (MAF< 0.01), and common
coding variants. This partitioned analysis identified a total
h2g of 0.079 (SE ¼ 0.034) from all coding variants (Table 2);
only the h2g of 0.042 (SE ¼ 0.017) from common coding
variants was significantly different from 0 (p ¼ 7.7 3
103; rare coding p ¼ 0:10). Moreover, the estimate of
DHS enrichment from common SNPs was unaffected by
the inclusion of rare coding variants (Table S24), confirm-
ing that DHS enrichment was not an artifact of untagged
coding variation in this cohort. The h2g from rare variants
remained nonsignificant even after we partitioned accord-
ing to PolyPhen-2 scores,52 restriction to putative SP-asso-
ciated genes (see Appendix A), or gene collapsing (Tables
S25 and S41–S43). This does not invalidate the use of
collapsed-gene burden tests for association and genetic
mapping because the individual collapsed gene is still aThe Americanfundamentally informative unit of association. It does,
however, demonstrate that the maximum variance that
can be explained by such methods is guaranteed to be sub-
stantially lower than that of association with the full
model, as has been shown in previous analyses of burden
tests.53 For singleton variants, we can place a 95% upper
bound on collapsed h2g at 0.014. We caution that our
exome-chip results pertain to rare variants included in
the chip design (ascertained from 12,000 samples) but do
not extend to extremely rare variants. However, our find-
ings are consistent with a recent analysis of SP exome
sequencing data, which identified a significant but modest
rare-coding burden (0.4%–0.6% of total variance) in a sub-
set of ~2,500 genes.54
Fine Mapping with Functional Priors
Estimates of functional h2g enrichment can guide fine-map-
ping analysis, where the goal is to identify a minimal set of
SNPs that include the underlying causal variant(s).55 To
investigate thepotential benefits of finemappingon theba-
sis of our estimates of functional enrichment, we applied
these estimates as priors for fine mapping in four traits
(RA, T2D, CAD, and SP) with publicly available imputed
summary statistics (Table S26; see Web Resources). We
used corresponding estimates of functional enrichment in
the WTCCC1 data for RA, T2D, and CAD (while implicitly
assuming a best-case scenario in which functional enrich-
ment was accurately estimated for each trait) and used esti-
mates of functional enrichment in PGC2 data for SP. Given
that SNPs at genome-wide-significant loci explain only a
small proportion of the trait variance, we do not expect par-
tial sample overlap tobe a significant confounder.Although
fine-mapping analysis ideally involves targeted sequencing
orgenotyping,Maller et al.55 observed that the latterhad lit-
tle impact on their fine-mapping analysis in comparison to
imputed data, sowe expect imputedmarkers to be a reason-
ableproxy. Each locuswasdefinedas theunionof1Mbwin-
dows aroundanySNPwith apvalue<53108. Association
statistics consisting of individual SNP effect sizes and SEs
were converted to Bayes factors as described in Pickrell13
and Wakefield56 and were multiplied by either a flat prior
or the genome-wide functional prior (computed as the esti-
mated h2g per SNP of the SNP category in the corresponding
trait). We then computed the credible set for each locus for
each scenario by including SNP Bayes factors from highest
to lowest until the sum of the Bayes factors in the set was
at least 95% of the sum of the Bayes factors at the locus.
On average, we found that the six main functional priors
reduced the credible set of causal variants by 30% across
the four traits (Table 3). The largest reduction of 63% was
observed in RA, where the total credible set for five loci
(excluding the MHC) was reduced from 69 SNPs to 26. For
comparison, including only coding-variant enrichment as
a prior reduced the credible sets by 5% on average and
had no reduction for RA. We showed by simulation that
the credible sets were well calibrated with the correct priors
andmiscalibrated by less than 10%when the priors were atJournal of Human Genetics 95, 535–552, November 6, 2014 545
Table 3. Credible Sets of Causal SNPs at Known Associated Loci
Phenotype No. of Loci Total SNPs Flat Prior Coding Prior Main Functional Priors Main and Enhancer Priors
RA 5 8,393 69 69 26 26
T2D 13 24,799 101 90 84 83
CAD 16 27,685 112 112 90 86
CAD (metabo-chip) 34 7,498 325 325 264 260
PGC2 146 582,401 5,696 5,660 4,756 not available
For each trait, genome-wide-significant loci from meta-analysis association statistics were reduced to 95% credible sets with and without functional priors. The
right-most four columns describe the number of SNPs in the credible set obtained from each prior type. ‘‘Flat prior’’ corresponds to standard analysis with no
functional information. ‘‘Coding prior’’ uses only enrichment at coding variants. ‘‘Main functional priors’’ include all six priors from the main functional analysis.
‘‘Main and enhancer priors’’ include all six main priors and the enhancer-DHS prior.the extremes of the meta-analysis estimates (Table S27),
demonstrating that this functional fine-mapping strategy
might become robust and effective as individual trait sam-
ple sizes reach the current meta-analysis sample size. How-
ever, we caution that our estimates of functional enrich-
ment for individual traits, except SP, are not tight enough
for this strategy to be actionable at the current time.Discussion
The importance of regulatory and cell-type-specific varia-
tion in common disease has previously been recog-
nized,3–10 but in contrast to previous work, we provide a
quantification of this contribution to disease heritability.
We have demonstrated by extensive simulations that our
variance-component strategy yields robust estimates that
account for LD between categories and complex-disease ar-
chitecture. Across 11 traits, we found that regulatory re-
gions marked by DHSs explained an average of 79% of
imputed h2g and 38% of genotyped h
2
g . We replicated our re-
sults in a large SP cohort, yielding a single-trait estimate of
3.23 (SE ¼ 0.29, p ¼ 1.4 3 1013) from imputed SNPs, and
found that the contribution from rare, exome-chip vari-
ants was nonsignificant and did not affect the enrichment.
Given that GWASs primarily identify noncoding vari-
ants, many hypotheses have been developed to explain
the architecture of complex traits, including noncoding
RNA, DNA methylation, alternative splicing, and unanno-
tated transcripts.14,57 Several previous studies have demon-
strated an excess of significant GWAS associations in
regulatory categories.5,6,11,58 In particular, Ernst et al.59
observed 23 enrichment in cell-type-relevant enhancers,
Schaub et al.8 identified 1.123 enrichment at DHSs, and
Maurano et al.3 identified 1.431.83 enrichment at
DHSs (relative to noncoding SNPs) and enrichment at
cell-type-relevant DHSs. In our analyzed cohorts, known
variants were1.73 enriched with DHSs, but there was less
enrichment at variants identified only in these cohorts.
In contrast, our findings constrain most of h2g to the 16%
of SNPs that lie in the DHS marks tested (or to SNPs that
lie very close to DHSs; see below), particularly in those
that overlap enhancers, and suggest that the other pro-546 The American Journal of Human Genetics 95, 535–552, Novembposed mechanisms are unlikely to make substantial inde-
pendent contributions. A deeper analysis of DHSs nar-
rowed to cover 1% of the genome still explained 20% of
h2g directly (and 61% in total), potentially motivating a
DHS-targeted genotyping chip analogous to the exome
chip.60 More generally, our approach provides a means of
assessing biological hypotheses of contributions to disease
heritability.
Unlike previous methods, our approach infers disease-
relevant biological function from all SNPs simultaneously
instead of one GWAS hit at a time. Overmultiple simulated
disease architectures, we show that variance-component
methods are more accurate in partitioning heritability
than summary-statistic-based approaches, such as p value
enrichment, despite the appeal of analyses of summary sta-
tistics in many contexts.61–64 For completeness, we also
considered two additional methods, stratified Q-Q plots12
and Bayesian hierarchical modeling (fgwas),13 which
assess functional enrichment but are primarily focused
on strong associations and improving mapping power.
These methods did not produce consistent estimates of
h2g enrichment either in simulations or in real data
(Figure S19–S29), although we note that they have
different objectives. In addition to having implications
for mapping power,12,13,65–68 functional enrichment has
direct implications for fine mapping55,69,70 and risk predic-
tion. Enrichments at the level we observed could substan-
tially reduce the set of potential causal variants in the four
traits we tested by downweighing SNPs in low-heritability
categories. On the other hand, the improvement in poly-
genic risk prediction was limited because of pervasive LD
across categories (Table S28).
Several limitations of our approach remain as avenues for
future work. The variance-component method might still
be subject to subtle biases21,41,42 under disease architectures
or annotations with complex LD structure, although our
analyses indicate that it is generally less biased than pub-
lished methods. In particular, we found that imputed data
might lead to an overestimate of category enrichment
from causal variation very close to that category. For
computational reasons, we did notmake use of themixture
of the normal-effect-size approach, which has been shown
to increase precision.24 The method also requireser 6, 2014
individual-level genotype data and is computationally
infeasible for extremely large cohorts or a very largenumber
of components, motivating further work on methods that
analyze summary statistics. A limitationof assessing enrich-
ment from GWAS platforms is that we cannot account for
untagged causal variation, which represents roughly half
of total narrow-sense heritability.71 Although we have
shown that rare coding variants are unlikely to alter the
DHS enrichment, themissing heritability could lie in other
categories. The precision of inferred enrichment is also
limited by the underlying annotations and variants. It is
possible that certain biological features could be subject to
systematically poorer variant calling or imputation and
exhibit decreased h2g as a result of artifacts,
72 although we
did not observe substantial differences in the categories
we analyzed. Because of the data available, our meta-anal-
ysis estimates were weighted toward autoimmune traits
both in thenumberof individual studies and in total sample
size; estimates of DHS enrichment were higher in autoim-
mune than in nonautoimmune traits, which could be
partly due to the abundance of hematopoietic cell types
in available DHS annotations. Except for SP, for which
many samples are available,we couldnotprovideprecise es-
timates for single traits. However, we have shown by simu-
lation that the individual estimates and errors were well
calibrated, justifying meta-analysis of estimates that are
not constrained to the plausible 0–1 range (an established
strategy49). Further partitioning of DHSs can yield addi-
tional enrichment, and it is likely that other functional cat-
egories—including additional chromatin marks, histone
modifications, formaldehyde-assisted isolation of regulato-
ry elements, transcription factor binding sites,73 gene
expression,58,74,75 and measures of conservation7—will be
highly informative.Appendix A
LD
We further interrogated the role of LD and violations of
model assumptions in the variance-component estimate.
We considered two contrived annotations constructed
from either the 16% of SNPs with the most LD partners
or the 16% of SNPs with the fewest LD partners to mimic
a high or low LD category, respectively, approximately
equal in SNP number to the DHS category. Testing the uni-
formly drawn MAF-independent architecture, we again
observed no enrichment for either the high-LD (1.023,
SE ¼ 0.01) or the low-LD (1.023, SE ¼ 0.03) annotations
over 1,000 trials. Finally, we considered a disease architec-
ture in which causal variants were strongly enriched at the
centers of DHSs such that variants in the middle 7% of
the DHS (1% of the genome) explained 25% of the h2g
and the remaining DHS variants explained 75% of the
h2g . We observed a slight deflation of the DHS estimate,
but no significant false enrichment, at the neighboring cat-
egories (Figure S20).The AmericanJackknife Estimates of SEs
The analytical SE used for significance testing was accurate
in our simulations (Table S29) and has previously been
shown to be robust in real data21,27 but can be biased
when the number of causal variants is very small.41 We as-
sessed this directly with a weighted-block jackknife esti-
mate76 of the enrichment in the real traits by dropping
each chromosome in turn, constructing new GRMs, and
recomputing the percentage of h2g for each functional cate-
gory (and the corresponding enrichment). The jackknife
estimate of the enrichment and its variance was then
computed as described in Busing et al.76 Although there
is a demonstrable relationship between chromosome
length and h2g , we do not expect to observe such a relation-
ship with respect to the percentage of h2g because of the
normalization. However, this estimate of the variance
does capture true biological variation in enrichment across
chromosomes and is therefore conservative. Although we
observed little difference between the jackknife and stan-
dard estimates in genotyped data (Table S30), the jackknife
estimate of the imputed percentage of h2g (71%, SE ¼ 7.7%;
Table S31) was indeed more conservative than the analyt-
ical estimate (79%, SE ¼ 6.6%), but the enrichment was
still highly significant (p¼ 5.53 1013), and the overall re-
sults were not substantially affected. Because the jackknife
makes no assumptions about the underlying distribution
of enrichment, this consistency with the analytical esti-
mate supports the use of REML SEs for case-control data
(see also simulations below).
Ancestry
We found little population structure in all of the traits
except for MS and SP (Figure S1), which have been previ-
ously reported as structured. For the MS cohort, we have
shown previously21 that rigorous ancestry matching did
not substantially change the total or partitioned h2g . For
the SP cohort, we relied on the consistently replicated
enrichmentacross thePGC2andSwedishSPcohorts,which
havebeen rigorously quality controlled for the avoidance of
population stratification. Recently, Janss et al.77 demon-
strated that h2g can vary significantly when principal com-
ponents are also included as fixed effects as a function of
thenumber of included eigenvectors. To assess thepresence
of this bias in our Swedish SP data, we recomputed the joint
variance-component estimates of bh2g while including an
increasing number of eigenvectors as fixed effects. We
observed no significant fluctuation of bh2g such that the esti-
mates over 1–20 eigenvector covariates had a SD of 0.002,
suggesting a tight estimate unbiased by the fixed effects.
Case-Control Ascertainment
Recent work37,78,79 has shown that liability-scale estimates
of h2g from REML can be biased downward in dichotomous
traits with strong case-control ascertainment. Golan and
Rosset78 and Hayeck et al.79 propose an alternative esti-
mator based on Haseman-Elston (H-E) regression80 and
show that it eliminates bias. In brief, this approachJournal of Human Genetics 95, 535–552, November 6, 2014 547
regresses the product of normalized phenotypes on the ge-
netic covariance (off-diagonal GRM entries) for all unique
pairs of samples; the resulting slope is used as an estimate
of the observed-scale h2g and is converted to the liability
scale. This method can be extended naturally to multiple
components, where the product of phenotypes is regressed
onto GRM entries from each analyzed component in a
multiple linear regression. Here, we compared the method
and transformation of Golan and Rosset78 to the REML
estimator described in the main text. We also evaluated
the impact of incorporating principal components as fixed
effects to account for genetic ancestry. This is particularly
important for the SP and MS cohorts (see below), which
were ascertained in a way that induces correlations be-
tween ancestry and phenotype. All analyses were per-
formed with the same set of GRMs computed from 1000
Genomes imputed data, and the H-E regression (and
H-E regression with fixed effects) was implemented as
described in Golan and Rosset.78 In all instances, we used
analytical error-covariance estimates and rescaled them
with the delta method to compute SEs. (We note that the
SE for H-E regression makes strongly violated assumptions
about independence, and they are therefore only pre-
sented for completeness). We observed little difference be-
tween variance-component methods and H-E regression
methods, and H-E regression yielded an average estimate
1.053 greater than that of REML and an overall r2 ¼ 0.95
between the two methods (across 11 traits; Table S32).
The relative performance was similar when we considered
only the percentage of h2g from the DHS component (Table
S33) such that H-E regression yielded average estimates
1.043 higher than those of REML and an overall r2 ¼
0.94. When principal components where included as fixed
effects, meta-analysis across traits within each method did
not yield significant differences (Table S34); H-E regression
identified DHS enrichment of 5.83 (SE ¼ 0.45), and REML
identified DHS enrichment of 5.13 (SE ¼ 0.42). When we
did not include principal components as fixed effects, we
observed a large difference between variance components
and H-E regression in the SP and MS cohorts, where liabil-
ity-scale H-E regression estimates of liability-scale h2g were
10.00 and 2.91, respectively (Table S32), outside the plau-
sible 0–1 bound and vastly larger than REML estimates
without fixed effects. This suggests that H-E-regression-
based estimates might be particularly sensitive to the con-
founding effects of ancestry.
Lastly, we repeated our null simulations by using the
merged WTCCC2 cohort of ~33,000 samples, allowing us
to simulate a case-control ascertainment (327 case and
654 control subjects) at a prevalence of 0.01 (see Table
S35 for simulation details). When we generated ~1,000
samples on chromosome 1 only, this simulated cohort
had an effective SNP-sample ratio (the key quantity driving
the effects of case-control ascertainment37) corresponding
to that of ~10,000 samples genome-wide. We tested a
‘‘polygenic’’ scenario where causal variants were sampled
uniformly, as well as a ‘‘high-effect’’ scenario where DHS548 The American Journal of Human Genetics 95, 535–552, Novembvariants had 103 the effect of other SNPs, and found no
significant deviation from the null estimate (Table S35)
or the analytical SE (Table S36). Although ascertainment
has previously been shown to induce correlation between
causal variants, our simulations indicate that this does not
bias estimates of enrichment for the prevalence and sam-
ple size simulated here.Detailed Analyses of Rare-Variant h2g
Having identified no significant rare-variant h2g at any
coding regions, we were interested in quantifying this phe-
nomenon at the set of loci known to be associated with SP.
To do so, we constructed six variance components only
from SNPs at the 22 loci identified by the PGC1 in a large
meta-analysis48 and estimated h2g jointly with a compo-
nent for the remaining noncoding variants genome-wide
(to account for tagging). As expected, we found the union
of all noncoding GWAS variants at these loci to harbor sig-
nificant heritability of 0.018 (SE¼ 0.004) (Table S37). How-
ever, we did not see any significant heritability from the
coding variants at these classes when they were modeled
jointly with the other component. This is consistent
with our genome-wide finding that common noncoding
variants explained a substantial fraction of trait heritability
and tagged nearly half of the common coding variation.
We also partitioned h2g at the set of 1,796 ‘‘composite’’
genes reported by Purcell et al.54 to exhibit enrichment
of rare disruptive mutations, modeled jointly with
exome-chip variants in the remaining genes and noncod-
ing GWAS-chip variants as separate components. However,
no significant h2g was observed at either the entire set of
composite variants (h2g ¼ 0.014, SE ¼ 0.012) or the rare
composite variants (h2g ¼ 0.008, SE ¼ 0.012).
We observed a significant enrichment in h2g at 4,919
(nonsingleton) loss-of-function variants, which collec-
tively accounted for 6.0% of (nonsingleton) exonic
SNPs but explained 24.3% of the exonic h2g (permuted
p ¼ 0.02 after MAF matching). We saw no significant
enrichment of h2g at coding sites that were predicted to
be functionally important by PolyPhen-2.52 Comparing
likelihoods between the model where variants were split
into (1) probably damaging and damaging, (2) benign
and other, and (3) noncoding components and the model
with only (1) coding and (2) noncoding components
yielded no significant difference by a 1-degree-of-freedom
likelihood-ratio test (p ¼ 0.13).Supplemental Data
Supplemental Data include 29 figures and 42 tables and can be
found with this article online at http://dx.doi.org/10.1016/j.
ajhg.2014.10.004.Consortia
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